Suppr超能文献

醋氯芬酸控释制剂治疗膝骨关节炎患者的疗效与安全性:一项为期4周的多中心随机对照临床研究。

Efficacy and Safety of Aceclofenac Controlled Release in Patients with Knee Osteoarthritis: A 4-week, Multicenter, Randomized, Comparative Clinical Study.

作者信息

Moon Young-Wan, Kang Seung-Baik, Kim Tae-Kyun, Lee Myung-Chul

机构信息

Department of Orthopedic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Department of Orthopedic Surgery, Seoul National University Boramae Hospital, Seoul, Korea.

出版信息

Knee Surg Relat Res. 2014 Mar;26(1):33-42. doi: 10.5792/ksrr.2014.26.1.33. Epub 2014 Feb 27.

Abstract

PURPOSE

To evaluate the analgesic effect, efficacy and safety of aceclofenac controlled release (CR) in patients with chronic knee osteoarthritis (OA).

MATERIALS AND METHODS

A total of 125 subjects with chronic knee OA were randomly divided into two groups: one group (n=62) was administered aceclofenac CR once daily and the other (n=63), aceclofenac immediate release (IR) twice a day for 4 weeks. A 100-mm visual analogue scale (VAS), Knee injury and Osteoarthritis Outcome Score (KOOS) and range of motoin (ROM) were evaluated as the outcome measures. To evaluate the safety of the drug, adverse events, vital signs, physical examination findings, clinical laboratory values and electrocardiographic findings were evaluated.

RESULTS

The VAS, KOOS and ROM were improved after 4 weeks of administration in both groups, but the differences between the two groups were not statistically significant. Significant differences between the two groups were not shown in the evaluation of the adverse events, vital sign, physical examination results, clinical laboratory values, and electrocardiography.

CONCLUSIONS

The aceclofenac CR and aceclofenac IR were equally effective in patients with chronic knee OA and the clinical trial results didn't show any significant difference in safety. The new aceclofenac CR formulation was found to be effective and safe with the practical advantage of once daily administration.

摘要

目的

评估醋氯芬酸控释片(CR)对慢性膝骨关节炎(OA)患者的镇痛效果、疗效及安全性。

材料与方法

125例慢性膝OA患者随机分为两组:一组(n = 62)每日服用一次醋氯芬酸CR,另一组(n = 63)每日服用两次醋氯芬酸速释片(IR),疗程4周。采用100毫米视觉模拟量表(VAS)、膝关节损伤和骨关节炎疗效评分(KOOS)以及运动范围(ROM)作为疗效指标。通过评估不良事件、生命体征、体格检查结果、临床实验室值和心电图结果来评价药物的安全性。

结果

两组给药4周后,VAS、KOOS和ROM均有所改善,但两组间差异无统计学意义。在不良事件、生命体征、体格检查结果、临床实验室值和心电图评估中,两组间均未显示出显著差异。

结论

醋氯芬酸CR和醋氯芬酸IR对慢性膝OA患者疗效相当,临床试验结果表明二者在安全性方面无显著差异。新型醋氯芬酸CR制剂有效且安全,具有每日一次给药的实际优势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a518/3953523/f2e76e5babe0/ksrr-26-33-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验